crfr

CP 376395 (CP-316311) is an effective and specific Corticotropin-releasing factor 1 (CRF1) receptor antagonist.

Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .

Urocortin, human (Human urocortin I) is a 40 amino acid peptide which is closely related to corticotrophin-releasing factor (CRF).

Corticotropin-releasing factor (human) acetate stimulates to synthesize and secret adrenocorticotropin in the anterior pituitary.

Urotensin I acetate (83930-33-0 Free base) is a CRF-like neuropeptide (natural product), a CRF receptor agonist (EC50 as low as 3.5 pM for hCRF1, Ki=0.4 nM), with high affinity and receptor subtype selectivity, used for CRF receptor functional research.

CP 316311 is a specific CRF1 receptor antagonist with potential antidepressant activity and may be used in the study of depression.

Crinecerfont (SSR-125543) is a selective antagonist of corticotropin-releasing factor 1 receptor (CRF1) and can be used in studies about Classic congenital adrenal hyperplasia.

(R)-Crinecerfont is an enantiomeric counterpart of SSR-125543. SSR-125543 is a potent CRF-R1 antagonist with Ki = 1.0 nM for human CRF-R1.

Urocortin (rat) acetate is a potent, selective CRFR agonist with Ki values of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α, and mouse CRF2β, respectively. Urocortin (rat) acetate exhibits cardioprotective, anti-inflammatory, and immunomodulatory activities. Urocortin (rat) acetate can be used in cardiovascular protection and immune-inflammatory research.

NVS-CRF38 is an antagonist of corticotropin-releasing factor receptor 1 (CRF1).

DMP 696 is a selective antagonist of corticotropin-releasing hormone receptor 1. It is used for the treatment of anxiety and depression.

Emicerfont is an antagonist of the corticotropin-releasing factor type 1 receptor (IC50: 66 nM).

Mepixanox is an analeptic drug. It is used for treating respiratory and cardiorespiratory insufficiency.

Pexacerfont (BMS-562086) is a selective antagonist of the corticotropin-releasing factor receptor (IC50: 6.1±0.6 nM for the human CRF1 receptor).

R121919 (NBI30775) is a potent small molecule antagonist of the adrenocorticotropic hormone-releasing factor receptor 1 (CRF1), demonstrating antidepressant and anxiolytic activity, and inhibiting the CRF1 receptor, CRF2 receptor, and CRF-binding proteins.

CRHR1 antagonist 1 (compound 10a) is a non-peptide antagonist of corticotropin-releasing hormone receptor 1 (CRHR1). It serves as a useful tool in the study of psychiatric disorders.

Antalarmin hydrochloride is an antagonist of corticotropin-releasing factor 1(CRF1). Antalarmin hydrochloride produces anti-inflammatory effects and suppresses stress-induced gastric ulceration related to irritable bowel syndrome.

CP 154526 hydrochloride is a blood-brain barrier-penetrant, selective CRF1 (corticotropin-releasing factor receptor 1) antagonist (Ki = 2.7 nM) exhibiting thousands of times greater selectivity for CRF1 over CRF2, with anxiolytic and antidepressant activities.

corticotropin-releasing factor1 (CRF1) receptor antagonist

NBI 35965 methanesulfonate  is a CRF1 antagonist.

SN 003 is a CRF1 antagonist.

JTC-017 is an antagonist of Corticotropin-releasing hormone receptor 1.

Tildacerfont is an antagonist of CRF1 and reduces the levels of adrenocorticotropic hormone and adrenal androgen. Tildacerfont can be used in studies about congenital adrenal hyperplasia.

BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM) that inhibits CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM). It is also efficacious in the Defensive Withdrawal model of anxiety in rats and has low in vivo clearance [Cl = 17 mL/min/kg, t½ = 7.8 h].